Skip to main content
SpringerLink
Log in

Peroxisome proliferator-activated receptor (PPAR)γ is highly expressed in normal human pituitary gland

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Objective: Expression of peroxisome proliferator-activated receptor (PPAR)γ in normal pituitary seems to be restricted to ACTH-secreting cells. The aim of the study was to evaluate the expression of PPARγ in normal human pituitary tissue and to study its localization in the pituitary secreting cells. Materials and methods: Normal pituitary tissue samples were obtained form 11 patients with non-secreting adenoma who underwent surgical excision of the tumor. Expression of PPAR? was evaluated by immunostaining and western blotting; localization of PPAR? in each pituitary secreting cell lineage was evaluated by double immunofluorescence using confocal microscopy. Pituitary non-functioning adenomas served as Controls. Results: PPARγ was highly expressed in all pituitary samples with a (mean±SD) 81±6.5% of stained cells; expression of PPARγ was confirmed by western blotting. Non-functioning pituitary adenomas had 74±11% PPAR? positive cells. Expression of PPARγ was either in cytoplasm or nuclei. In addition, treatment of GH3 cells, with a PPARγ ligand was associated with traslocation of the receptor from cytoplasm into the nucleus. Double immunostaining revealed that every pituitary secreting cell (GH, TSH, LH, FSH, PRL and ACTH) had PPARγ expressed. Discussion: The present study demonstrated that PPARγ is highly expressed in every normal pituitary secreting cell lineage. It can translocate into the nucleus by ligand binding; however, its role in pituitary hormone regulation remains to be elucidated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Desvergne B, Wahli W. Peroxisome proliferator activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20: 649–88.

    PubMed  CAS  Google Scholar 

  2. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004, 25: 331–6.

    Article  PubMed  CAS  Google Scholar 

  3. Lowell BB. PPARγ: an essential regulator of adipogenesis and modulator of fat cell function. Cell 1999, 99: 239–42.

    Article  PubMed  CAS  Google Scholar 

  4. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma lig-ands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000, 106: 523–31.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  5. Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 2001, 7: 395–400.

    Article  PubMed  CAS  Google Scholar 

  6. Demetri GD, Fletcher CDM, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-? ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999, 96: 3951–6.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  7. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for per-oxisome proliferator-activated receptor ? (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998, 58: 3344–52.

    PubMed  CAS  Google Scholar 

  8. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004, 10: 355–61.

    Article  PubMed  CAS  Google Scholar 

  9. Zander T, Kraus JA, Grommes C, et al. Induction of apop-tosis in human and rat glioma by antagonist of the nuclear receptor PPARgamma. J Neurochem 2002, 81: 1052–60.

    Article  PubMed  CAS  Google Scholar 

  10. Ohta K, Endo T, Haraguchi K, et al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001, 86: 2170–7.

    PubMed  CAS  Google Scholar 

  11. Desvergne B, Michalik L, Whali W. Be fit or be sick: peroxi-some proliferator-activated receptors are down the road. Mol Endocrinol 2004, 18: 1321–2.

    Article  PubMed  CAS  Google Scholar 

  12. Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 2003, 3: S17–21.

    Article  CAS  Google Scholar 

  13. Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002, 8: 1281–7.

    Article  PubMed  CAS  Google Scholar 

  14. Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003, 111: 1381–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  15. Bogazzi F, Ultimieri F, Raggi F, et al. PPARγ inhibits GH syntesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol 2004, 150: 863–75.

    Article  PubMed  CAS  Google Scholar 

  16. Ambrosi B, Dall’Asta C, Cannavo S, et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing’s disease. Eur J Endocrinol 2004, 151: 173–8.

    Article  PubMed  CAS  Google Scholar 

  17. Cannavo’ S, Ambrosi B, Chiodini I, et al. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma lig-and, rosiglitazone, in Cushing’s disease. J Endocrinol Invest 2004, 27: RC8–11.

    Google Scholar 

  18. Shibuya A, Wada K, Nakajima A, et al. Nitration of PPARg inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Letters 2002, 525: 43–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy

    F. Bogazzi, D. Russo, F. Ultimieri, F. Raggi, C. Cosci, C. Sardella, M. Gasperi & E. Martino

  2. Department of Oncology, University of Pisa, Pisa, Italy

    M. T. Locci, B. Chifenti, P. Viacava & D. Cecchetti

  3. Department of Neurosurgery, University of Pisa, Pisa, Italy

    G. Acerbi

Authors
  1. F. Bogazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. T. Locci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Chifenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Ultimieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Raggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Viacava
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Cecchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Cosci
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. Sardella
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. Acerbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. Gasperi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E. Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bogazzi, F., Russo, D., Locci, M.T. et al. Peroxisome proliferator-activated receptor (PPAR)γ is highly expressed in normal human pituitary gland. J Endocrinol Invest 28, 899–904 (2005). https://doi.org/10.1007/BF03345321

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345321

Key-words

Search

Navigation